Search results
Actinium Announces Multiple Abstracts Highlighting its Antibody Radiation Conjugates Iomab-B and...
WJTV Jackson· 4 days agoActinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of Antibody Radiation Conjugates (ARCs) and other targeted radiotherapies ...
Johnson & Johnson to acquire Proteologix for $850 million By Reuters
Investing.com· 1 day agoProteologix's antibody PX128 is ready to enter early-stage development for moderate to severe atopic...
IGM Biosciences Inc (IGMS) Q1 2024 Earnings: Aligns with EPS Pro
Guru Focus· 7 days agoIGM Biosciences operates as a clinical-stage biotechnology firm focusing on the creation and development of IgM antibody therapeutics. Its innovative IgM antibody ...
Analysts weigh in on FDA's approval for Amgen's small cell cancer drug
Investing.com· 13 hours agoThe approval is specifically for cases that have progressed following chemotherapy treatments....
The Jackson Laboratory and AbTherx Announce Partnership to Enhance Therapeutic Antibody Discovery
Casper Star-Tribune· 7 days agoThe Jackson Laboratory (JAX), an independent, nonprofit biomedical research organization, and AbTherx, an innovator in biotechnology, announced a strategic partnership to develop and commercialize ...
Antibodies in vaccine-induced blood clots show the | Newswise
Newswise· 4 days agoThe antibodies formed in classic vaccine-induced immune thrombocytopenia and thrombosis (VITT) are essentially identical as those formed in the VITT-mimicking disorder triggered by natural adenovirus ...
Genetics Played a Role in Blood Clots Linked to COVID-19 Shots
Time Magazine· 2 days agoRare but deadly blood clots tied to Johnson & Johnson and AstraZeneca Plc’s Covid-19 shots were...
Small Business - The Brewton Standard | The Brewton Standard
The Brewton Standard· 3 days agoAlchemab Therapeutics (Alchemab), an antibody discovery company identifying naturally occurring antibodies from individuals resilient to disease, today announces the publication ...
Third Party Withdraws Appeal Related to Cantargia Patent
Digital Journal· 1 day agoThereby, the patent remains in force with claims encompassing treatment of solid tumours by anti-IL1RAP-targeting antibody, as originally decided by the EPO Opposition Division ...
Aptevo Therapeutics Presenting at The Protein & Antibody Engineering Summit, Boston, MA
Digital Journal· 3 days agoThe session, being offered today, Tuesday May 14, 2023 at 8:30 AM Eastern time and entitled " Development of Target...